Jump to page content

Steven Carr and Namrata Udeshi have made seminal contributions to the proteomics field, as they have co-developed with Alice Ting the APEX technology for spatial proteome mapping, were among the first to report on comprehensive proteogenomic cancer studies, and have set new standards for deep ubiquitinome profiling. The latter helped to unravel the mechanism of action of lenalidomide, a drug derivate of thalidomide (contergan), and allowed to identify drug response protein biomarkers for lenalidomide in multiple myeloma.


Steven Carr (Director of Proteomics Platform)
“Microscaled Proteomics for Cancer Research and New Approaches for Spatially Resolved Proteomic Mapping”

Namrata Udeshi (Senior Group Leader)
“Proteomic Techniques for Ubiquitylation Profiling in Cancer”

About Steven Carr

Steven Carr is Director of Proteomics at the Broad Institute of MIT and Harvard. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine.

Steven and his group collaborate with scientists throughout the Broad Institute community (Harvard University, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine. Research in his lab focuses on detecting and quantifying post-translational modifications (e.g., phosphorylation, acetylation, ubiquitylation, methylation, etc.) in the proteome, developing new technologies to quantify proteins in cells and biofluids with high sensitivity and specificity, improving informatics for peptide and protein assignment using mass spectrometry (MS) data, and integrating MS-derived data with genomic data. The Carr group is also known for developing and applying systematic approaches for biomarker discovery and validation to ultimately provide biomarkers for cancers, heart disease, infectious diseases, and metabolic disorders. He has over 225 publications on the development and use of proteomics and biological mass spectrometry.
Prior to joining the Broad Institute in 2004, Steven held scientific leadership positions in the pharmaceutical and biotechnology industries, including GlaxoSmithKline and Millennium. Steven is the recipient of a number of awards, including the 2011 Discovery Award in Proteomics from the Human Proteome Organization, the 2011 Thought Leader Award in Proteomics from the Agilent Foundation, and the 2014 Wallace H. Coulter Lectureship Award.

About Namrata Udeshi

Namrata Udeshi is a Senior Group leader in the Proteomics Platform of the Broad Institute of MIT and Harvard. She obtained her Phd in analytical chemistry in the group of Donald Hunt, University of Virginia, in 2009 and has been working as a postdoc, staff scientist and group leader at the Broad Institute over the last 10 years. She has made seminal contributions to the proteomics field, with a focus on spatial proteomics and ubiquitin-mediated proteome regulation, and has published >40 publications in high ranking journals.

The Technology Platform Proteomics is co-funded and integrative infrastructure of the Berlin Institute of Health (BIH).


11 March 2019
10:30 am


Max-Delbrück-Centrum für Molekulare Medizin
Robert-Rössle-Str. 10
Axon 1, MDC.C
Campus Berlin Buch
13125 Berlin


Dr. rer. nat. Philipp Mertins
Head of Proteomics Platform
Max Delbrück Center for Molecular Medicine in the Helmholtz Association
Robert-Rössle-Str. 10
Building 31.1, room 4018
13125 Berlin, Germany